40 -11 (85) 2025 - Sh.A. Naimova, N.A. Rakhimov - CLINICAL SIGNIFICANCE OF HEMOSTASIS BIOMARKERS IN PREVENTING POST-PCI RESTENOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

CLINICAL SIGNIFICANCE OF HEMOSTASIS BIOMARKERS IN PREVENTING POST-PCI RESTENOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE

Sh.A. Naimova - Bukhara State Medical Institute named after Abu Ali ibn Sina

N.A. Rakhimov - Bukhara Multidisciplinary Medical Center

Resume

In patients with type 2 diabetes mellitus combined with ischemic heart disease, the risk of coronary artery restenosis following percutaneous coronary intervention (PCI) remains significantly high, and alterations in hemostasis play a major role in its development. This study aimed to evaluate the prognostic clinical significance of hemostatic biomarkers (D-dimer, fibrinogen, platelet count, APTT, PT, INR) in predicting restenosis after PCI, to establish individualized preventive therapeutic strategies, and to optimize antiplatelet/anticoagulant treatment approaches. The findings demonstrated a strong association between prothrombotic changes in the hemostasis system and restenosis development. Integrative biomarker-based analysis can serve as a practical tool for early risk stratification and implementation of personalized preventive approaches in clinical practice.

Keywords: type 2 diabetes mellitus, ischemic heart disease, percutaneous coronary intervention, restenosis, hemostasis system, D-dimer, fibrinogen, antiplatelet therapy, anticoagulant therapy, prognostic marker.

First page

224

Last page

227

For citation:Sh.A. Naimova, N.A. Rakhimov - CLINICAL SIGNIFICANCE OF HEMOSTASIS BIOMARKERS IN PREVENTING POST-PCI RESTENOSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ISCHEMIC HEART DISEASE//New Day in Medicine 11(85)2025 224-227 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

1. Aboyans, V., Ricco, J. B., Bartelink, M. (2018). 2017 ESC guidelines on peripheral arterial diseases. // European Heart Journal 2018;39(9):763-816.
2. Bai, Y., Zhang, J., Chen, J., Li, Y. (2020). D-dimer to fibrinogen ratio predicts clinical restenosis after PCI. Cardiovascular Therapeutics, 2020;38(3):e7453438.
3. Beckman, J. A., Creager, M. A., Libby, P. (2002). Diabetes and atherosclerosis epidemiology, pathophysiology, and clinical implications. // Circulation, 2002;105:1135-1143.
4. Bianco M., et al. (2023). IL-6 and hs-CRP as predictors of in-stent restenosis after PCI. // Journal of Interventional Cardiology, 2023; Article ID 885492.
5. Choi, S. G., et al. (2022). Impact of glycemic control on restenosis progression after coronary stenting in diabetic patients. // Cardiovascular Diabetology 2022;21:145.
6. De Caterina, R., et al. (2020). Antithrombotic therapy in coronary disease: From ESC Guidance. // European Heart Journal Supplements, 2020;22:40-52.
7. Friedman J., et al. (2021). Hemostatic biomarkers and cardiovascular risk assessment in diabetes. // Thrombosis and Haemostasis 2021;121(1):16-27.
8. Galli L., et al. (2024). Platelets, biomarkers of coagulation and fibrinolysis in stent-related complications. // Journal of Clinical Medicine 2024;14(1):56.
9. Han Y., et al. (2021). Systemic inflammation and restenosis development. Frontiers in Cardiovascular Medicine, 2021;8:690212.
10. Kereiakes D. J., et al. (2019). Diabetes and restenosis following PCI: Current perspective. // JACC Cardiovascular Interventions, 2019;12(1):98-108.
11. Libby, P., Ridker, P. (2004). Inflammation and atherosclerosis. // Circulation 2004;109:II3–II11.
12. Prisco D., et al. (2001). PAI-1 activity as a risk marker of postprocedural coronary restenosis. // Journal of Thrombosis and Haemostasis 2001;86(4):1167-1172.
13. Sianos G., et al. (2020). Restenosis predictors in diabetic patients post PCI. // Catheterization and Cardiovascular Interventions 2020;96(7):1467-1475.
14. Soomro A.Y., et al. (2016). D-dimer role in clinical cardiovascular disease progression. European Heart Journal - Cardiovascular Pharmacotherapy, 2016;(3):175-183.
15. Xu W., et al. (2023). Glycemic variability and in-stent neointimal hyperplasia after PCI in T2DM. // Metabolism 2023;141:155-413.

    file

    download